April 24th 2024
During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants how their experience with immunotherapy toxicities has changed over time in the first article of a 2-part series.
December 19th 2023
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
AACR Meeting Focuses on Advances in Immunotherapy Across Several Cancer Types
May 22nd 2019Robert L. Ferris, MD, PhD, co-physician editor-in-chief of <em>Targeted Therapies in Oncology</em>, highlights a series of exciting results presented across various topics, which affect cancer research and treatment, during the 2019 AACR Annual Meeting.
Read More
Melanoma Investigators Strive to Overcome PD-1 Inhibitor Resistance
May 17th 2019Investigators across the globe have expended considerable effort attempting to identify mechanisms of response and resistance to ICIs. The general conclusion is that each patient’s response to immunotherapy is likely complex and highly individualized.
Read More
Novel Immunotherapy Tebentafusp Granted Fast Track Designation for Metastatic Uveal Melanoma
April 12th 2019The FDA has granted tebentafusp (IMCgp100) a fast track designation for the treatment of patients with HLA-A*0201-positive previously untreated metastatic uveal melanoma, according to Immunocore Limited, the company developing the novel immunotherapy agent.
Read More
Patient Misconceptions About Clinical Trials Are a Common Source of Resistance, Expert Panel Says
April 8th 2019Before a community oncology practice considers getting involved in clinical trials research, there are many factorsto consider. Perhaps foremost is the fact that cancer clinical trials provide the evidence base for new advances in oncology.
Read More
Despite Slow Adoption, Artificial Intelligence Pilot Programs Yield Practical Results
April 6th 2019Artificial intelligence has made inroads in many industries—banking, finance, security—but its adoption in healthcare has been lagging and real-world clinical implementation has yet to become a reality. Nonetheless, proponents say it is only a matter of time and pilot programs are starting to yield some practical results.
Read More
PD-1/HDAC Inhibitor Combo Active in Recurrent Melanoma After Progression on Anti-PD-1 Therapy
April 4th 2019Entinostat in combination with pembrolizumab induced responses in patients with recurrent or metastatic melanoma who have progressed on or after prior anti–PD-1 therapy, according to results of a phase II trial.
Read More
Challenges Persist With CAR T-Cell Therapy in Pancreatic Cancer
April 2nd 2019The success of chimeric antigen receptor T-cell therapy observed in hematologic malignancies has not yet translated into the solid tumor setting; however, efforts continue to try to bring this new modality into the treatment paradigm for solid tumors, including pancreatic cancer.
Read More
Childhood Cancer Associated With Increased Risk for Developing Skin Cancers
March 27th 2019According to new data, survivors of childhood cancer who have lived 5 or more years from their primary malignancy may be up to 30 times more likely to develop a skin malignancy compared with the general population.
Read More
CMS Mulls Opposition to Downsizing Part D Protected Drug Classes
March 15th 2019The healthcare community is still awaiting a response from the Centers for Medicare & Medicaid Services to the opposition of the agency’s proposal to substantially revise the Medicare Part D protected drug classes.
Read More
Evolving Standards of Care in Melanoma and Non-Small Cell Lung Cancer
March 14th 2019Robert L. Ferris, MD, PhD, Co-Physician Editor in Chief, <em>Targeted Therapies in Oncology</em>,<em> </em>discusses<em> </em>the<em> </em>evolving<em> </em>role of immunotherapy in melanoma and non–small cell lung cancer, where by it is now the dominant therapeutic approach in these diseases in progressively earlier lines of therapy.
Read More
Avoiding Overtreatment Saves Medicare $320M Over 3-Year Period in Older Men With Prostate Cancer
March 13th 2019Overtreating men 70 years or older with prostate cancer cost Medicare more than $1.2 billion from 2004 to 2007, according to the results of a retrospective study using the Surveillance, Epidemiology, and End Results–Medicare linked database.
Read More
Optimizing Adjuvant Strategies Extends RFS in High-Risk Melanoma
March 11th 2019In his presentation at the 2019 Annual Practical Recommendations in Immuno and Molecular Oncology Meetingi, Sanjiv S. Agarwala, MD, reviewed survival statistics of patients with melanoma being treated at different stages of their disease.
Read More